

BOARD OF SUPERVISORS AGENDA LETTER

Agenda Number:

Clerk of the Board of Supervisors

105 E. Anapamu Street, Suite 407 Santa Barbara, CA 93101 (805) 568-2240

Department Name: Public Health

Department No.: 041

For Agenda Of: July 25, 2017

Placement: Administrative

Estimated Time:

Continued Item: N_O

If Yes, date from:

Vote Required: 4/5

TO: Board of Supervisors

FROM: Department Carrie Topliffe, Interim Department Director

Director(s) 681-5105

Contact Info: Susan Klein-Rothschild, Deputy Director

681-5435

SUBJECT: Naloxone Grant Program

County Counsel Concurrence

Auditor-Controller Concurrence

As to form: Yes As to form: Yes

Other Concurrence: N/A

As to form:

Recommended Actions:

That the Board of Supervisors considers the following recommendations regarding grant funding for the Naloxone Distribution Project for the provision of naloxone to block opioid overdose in the community:

- a) Approve, ratify, and authorize the Public Health Director to execute Agreement # 16-11043 with the California Department of Public Health for the Naloxone Distribution Project (Attachment A) for the period July 1, 2017 through June 30, 2019 where the Department will receive doses of naloxone (value of \$34,755) for distribution to local entities;
- b) Approve and authorize the Public Health Director to make the required certification(s) of Agreement # 16-11043 with the California Department of Public Health;
- c) Approve budget revision request No. 0005227 (Attachment B) to add revenues and offset increased appropriations in the amount of \$34,755 in FY 2017-18; and
- d) Determine that these activities are not a project under the California Environmental Quality Act (CEQA) and are exempt from environmental review per CEQA Guideline Section 15378(b)(4), since they are a government fiscal activity that does not involve a commitment to a specific project that may result in a potentially significant effect on the environment.

Summary Text:

This item is on the agenda to approve and execute an agreement with the California Department of Public Health (CDPH) (Attachment A) to accept two distributions of naloxone, which is a lifesaving drug that blocks opioid overdose, from the CDPH to be distributed among local entities. CDPH is

providing these doses of naloxone to local health departments as a non-competitive grant. The Public Health Department (PHD) will distribute the product to local entities with existing naloxone programs and distribution systems in place in the community.

Background:

Drug overdose is the leading cause of unintentional injury death in the United States, causing more deaths than motor vehicle crashes. Opioids – both prescription painkiller and heroin – are responsible for most of those deaths. Opioids cause death by slowing and eventually stopping the person's breathing.

Naloxone nasal spray is an approved medication through the U.S. Food and Drug Administration. Naloxone works by temporarily blocking the effects of opioids. When administered, naloxone, also known as Narcan, restores central nervous system functions including respirations within two to five minutes, and may prevent brain injury and death. It literally saves lives. Naloxone has no potential for abuse and has no known adverse effects on persons who are not experiencing an opioid overdose.

In 2015, with funding from the Centers for Disease Control and Prevention (CDC), California initiated the California Prescription Drug Overdose Prevention Initiative to promote a multi-faceted statewide response involving many partners and a variety of strategies.

The CDPH naloxone grant program is one of the strategies. The grant is entirely in kind and provides that PHD will receive, store, and distribute naloxone. PHD submitted a non-competitive grant application on April 25, 2017.

This grant program requires PHD to:

- Identify entities within our health jurisdiction that already have naloxone distribution systems in place and have the capacity to efficiently and effectively provide naloxone and training to first responders;
- Select local entities to receive naloxone based on the level of risk of overdose among the populations they serve;
- Submit a naloxone distribution plan for approval;
- Begin distributing the naloxone product to selected entities 60 days after executed agreement;
- Document and submit the final report to the California Department of Public Health by April 1, 2019; and
- Enter into an agreement (Attachment A) with the California Department of Public Health.

The Public Health Department will work in collaboration with the Department of Behavioral Wellness and others to identify and select local entities, distribute the naloxone product and meet the grant requirements.

Performance Measure:

Distribution of doses to local entities that will be described in our Naloxone Distribution Plan once it's developed.

Fiscal and Facilities Impacts:

Budgeted: No

Fiscal Analysis:

Executing this agreement will result in additional revenues and offsetting increased appropriations in the amount of \$34,755. The contract term extends from 6/1/2017 to 6/30/2019. The revenues received will be in the form of naloxone nasal spray. The Public Health Department expects the naloxone to be delivered in two shipments during FY 2017-18. The attached Budget Revision (Attachment B) request adds needed revenues and appropriations in the amount of \$34,755 in FY 2017-18.

There is no increase in the use of the County's General Fund resources as a result of executing this agreement.

Key Contract Risks:

N/A

Staffing Impacts:

<u>Legal Positions:</u>
0

FTEs:

Special Instructions:

Please send an electronic copy of the Minute Order to the PHD Contracts Unit at: PHDCU@sbcphd.org

Attachments:

- A. California Department of Public Health Agreement for the Naloxone Distribution Project
- B. Budget Journal Entry Number: BJE #0005227

Authored by:

Susan Klein-Rothschild, MSW, Deputy Director